Esperion Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $51,632 | $73,834 | $137,735 | $32,250 |
Gross Profit | 34,346 | 58,215 | 127,660 | 20,792 |
EBITDA | -14,416 | -48,192 | 75,046 | -41,281 |
EBIT | -14,442 | -48,202 | 75,005 | -41,287 |
Net Income | -29,524 | -61,925 | 61,022 | -56,344 |
Net Change In Cash | 51,632 | 73,834 | 137,735 | 32,250 |
Free Cash Flow | -35,492 | -7,282 | 53,755 | -37,056 |
Cash | 144,717 | 189,304 | 226,609 | 82,248 |
Basic Shares | 194,930 | 188,793 | 189,641 | 112,403 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $116,334 | $75,475 | $78,447 | $227,547 |
Gross Profit | 73,067 | 48,508 | 64,230 | 225,155 |
EBITDA | -150,108 | -176,349 | -222,143 | -120,334 |
EBIT | -150,272 | -176,849 | -222,755 | -120,881 |
Net Income | -209,248 | -287,817 | -318,824 | -166,189 |
Net Change In Cash | 116,334 | 75,475 | 78,447 | 227,547 |
Cost of Revenue | -134,117 | -46,070 | 137,904 | |
Free Cash Flow | -135,487 | -174,827 | -263,809 | -98,546 |
Cash | 82,248 | 124,775 | 208,892 | 304,962 |
Basic Shares | 103,106 | 66,407 | 28,902 | 27,473 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.15 |
2024-06-30 | -$0.33 |
2024-03-31 | $0.34 |
2023-12-31 | -$0.50 |
